Alessandro Dalpiaz

List of Publications by Year
in descending order

89 papers	2,648 citations	172207 29 h-index	214527 47 g-index
89 all docs	89 docs citations	89 times ranked	3403 citing authors

#	Article	IF	Citations
1	Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach. Molecules, 2008, 13, 1035-1065.	1.7	124
2	Solid microparticles based on chitosan or methyl-Î²-cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. Journal of Controlled Release, 2015, 201, 68-77.	4.8	116
3	Design, Synthesis and Activity of Ascorbic Acid Prodrugs of Nipecotic, Kynurenic and Diclophenamic Acids, Liable to Increase Neurotropic Activity. Journal of Medicinal Chemistry, 2002, 45, 559-562.	2.9	99
4	Pharmacological and biochemical characterization of purified A_{2a} adenosine receptors in human platelet membranes by [³H]â€CGS 21680 binding. British Journal of Pharmacology, 1996, 117, 1693-1701.	2.7	79
5	Can thermodynamic measurements of receptor binding yield information on drug affinity and efficacy?. Biochemical Pharmacology, 2000, 60, 1549-1556.	2.0	76
6	Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review. Journal of Drug Delivery Science and Technology, 2016, 32, 77-87.	1.4	66
7	Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 250-259.	2.0	64
8	Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 309-320.	2.0	64
9	Preparation and characterization of starch/cyclodextrin bioadhesive microspheres as platform for nasal administration of Gabexate Mesylate (FoyÂ®) in allergic rhinitis treatment. Biomaterials, 2004, 25, 159-170.	5.7	62
10	Brain uptake of an anti-ischemic agent by nasal administration of microparticles. Journal of Pharmaceutical Sciences, 2008, 97, 4889-4903.	1.6	62
11	Zidovudine and Ursodeoxycholic Acid Conjugation: Design of a New Prodrug Potentially Able To Bypass the Active Efflux Transport Systems of the Central Nervous System. Molecular Pharmaceutics, 2012, 9, 957-968.	2.3	60
12	Geraniol Pharmacokinetics, Bioavailability and Its Multiple Effects on the Liver Antioxidant and Xenobiotic-Metabolizing Enzymes. Frontiers in Pharmacology, 2018, 9, 18.	1.6	60
13	Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson's disease. Journal of Controlled Release, 2020, 321, 540-552.	4.8	57
14	Binding thermodynamics of adenosine A2a receptor ligands. Biochemical Pharmacology, 1995, 49, 461-469.	2.0	56
15	Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Antiviral Research, 2015, 123, 146-157.	1.9	56
16	Adenylyl cyclases as innovative therapeutic goals. Drug Discovery Today, 2009, 14, 982-991.	3.2	55
17	Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targeting. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 174-183.	2.0	53
18	Influence of Chitosan Glutamate on the in vivo Intranasal Absorption of Rokitamycin from Microspheres. Journal of Pharmaceutical Sciences, 2011, 100, 1488-1502.	1.6	51

#	Article	IF	Citations
19	Responses of peripheral blood mononucleated cells from non-celiac gluten sensitive patients to various cereal sources. Food Chemistry, 2015, 176, 167-174.	4.2	51
20	Indomethacin Co-Crystals and Their Parent Mixtures: Does the Intestinal Barrier Recognize Them Differently?. Molecular Pharmaceutics, 2015, 12, 1501-1511.	2.3	51
21	Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors. Biochemical Pharmacology, 1998, 56, 1437-1445.	2.0	50
22	Brain Uptake of a Zidovudine Prodrug after Nasal Administration of Solid Lipid Microparticles. Molecular Pharmaceutics, 2014, 11, 1550-1561.	2.3	47
23	Can pharmaceutical co-crystals provide an opportunity to modify the biological properties of drugs?. Drug Discovery Today, 2017, 22, 1134-1138.	3.2	47
24	Characterization of A2A adenosine receptors in human lymphocyte membranes by [3 H]-SCH 58261 binding. British Journal of Pharmacology, 1997, 122, 386-392.	2.7	41
25	Receptor binding thermodynamics as a tool for linking drug efficacy and affinity. Il Farmaco, 1998, 53, 249-254.	0.9	38
26	Design, synthesis and in vitro evaluation on HRPE cells of ascorbic and 6-bromoascorbic acid conjugates with neuroactive molecules. Bioorganic and Medicinal Chemistry, 2004, 12, 5453-5463.	1.4	34
27	From Physical Mixtures to Co-Crystals: How the Coformers Can Modify Solubility and Biological Activity of Carbamazepine. Molecular Pharmaceutics, 2018, 15, 268-278.	2.3	34
28	Ascorbic and 6-Br-ascorbic acid conjugates as a tool to increase the therapeutic effects of potentially central active drugs. European Journal of Pharmaceutical Sciences, 2005, 24, 259-269.	1.9	33
29	Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?. Current Pharmaceutical Design, 2011, 17, 3560-3576.	0.9	33
30	The Role of Combined Penetration Enhancers in Nasal Microspheres on In Vivo Drug Bioavailability. Pharmaceutics, 2018, 10, 206.	2.0	31
31	A Novel Conjugated Agent between Dopamine and an A_{2A} Adenosine Receptor Antagonist as a Potential Anti-Parkinson Multitarget Approach. Molecular Pharmaceutics, 2012, 9, 591-604.	2.3	29
32	Thermodynamics of 5-HT3 receptor binding discriminates agonistic from antagonistic behaviour. European Journal of Pharmacology, 1996, 298, 329-334.	1.7	28
33	Compost use in viticulture: Effect on heavy metal levels in soil and plants. Communications in Soil Science and Plant Analysis, 1999, 30, 1531-1549.	0.6	28
34	Complementary use of flow and sedimentation field-flow fractionation techniques for size characterizing biodegradable poly(lactic acid) nanospheres. Journal of Chromatography A, 2007, 1157, 321-335.	1.8	28
35	Influence of secondary preparative parameters and aging effects on PLGA particle size distribution: a sedimentation field flow fractionation investigation. Analytical and Bioanalytical Chemistry, 2013, 405, 703-711.	1.9	28
36	Full and partial agonistic behaviour and thermodynamic binding parameters of adenosine A1 receptor ligands. European Journal of Pharmacology, 1994, 267, 55-61.	2.7	27

#	Article	IF	Citations
37	Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist. British Journal of Pharmacology, 2006, 147, 533-541.	2.7	27
38	Multidrug resistance in cancer or inefficacy of neuroactive agents: innovative strategies to inhibit or circumvent the active efflux transporters selectively. Drug Discovery Today, 2014, 19, 1563-1571.	3.2	27
39	Phe-d-Leu-Phe-d-Leu-Phe derivatives as formylpeptide receptor antagonists in human neutrophils: cellular and conformational aspects. BBA - Proteins and Proteomics, 1999, 1432, 27-39.	2.1	26
40	Synthesis and study of 5'-ester prodrugs of N6-cyclopentyladenosine, a selective A1 receptor agonist. Pharmaceutical Research, 2001, 18, 531-536.	1.7	26
41	Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?. Pharmaceutics, 2018, 10, 39.	2.0	26
42	Binding thermodynamics of 5-HT1A receptor ligands. European Journal of Pharmacology, 1996, 312, 107-114.	1.7	25
43	Polymeric Nanoparticles as Drug controlled Release Systems: A New Formulation Strategy for Drugs with Small or Large Molecular Weight. Journal of Nanoscience and Nanotechnology, 2006, 6, 3070-3079.	0.9	25
44	Retinal pigment epithelial cells as a therapeutic tool and target against retinopathies. Drug Discovery Today, 2018, 23, 1672-1679.	3.2	25
45	Application of the â€œin-oil nanoprecipitationâ€•method in the encapsulation of hydrophilic drugs in PLGA nanoparticles. Journal of Drug Delivery Science and Technology, 2016, 32, 283-290.	1.4	24
46	Exploring the use of spray congealing to produce solid dispersions with enhanced indomethacin bioavailability: In vitro characterization and in vivo study. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 139, 132-141.	2.0	23
47	Adenosine A1 Receptor: Analysis of the Potential Therapeutic Effects Obtained by its Activation in the Central Nervous System. Current Medicinal Chemistry, 2002, 9, 1923-1937.	1.2	22
48	C- and N-terminal residue effect on peptide derivatives' antagonism toward the formyl-peptide receptor. European Journal of Pharmacology, 2002, 436, 187-196.	1.7	22
49	Development and characterization of biodegradable nanospheres as delivery systems of anti-ischemic adenosine derivatives. Biomaterials, 2005, 26, 1299-1306.	5.7	22
50	Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 91-100.	2.0	22
51	Transporter-Mediated Effects of Diclofenamic Acid and its Ascorbyl Pro-Drug in the in Vivo Neurotropic Activity of Ascorbyl Nipecotic Acid Conjugate. Journal of Pharmaceutical Sciences, 2004, 93, 78-85.	1.6	21
52	Cancer stem cells and nanomedicine: new opportunities to combat multidrug resistance?. Drug Discovery Today, 2020, 25, 1651-1667.	3.2	20
53	Solid Lipid Nanoparticles as Formulative Strategy to Increase Oral Permeation of a Molecule Active in Multidrug-Resistant Tuberculosis Management. Pharmaceutics, 2020, 12, 1132.	2.0	19
54	Binding Thermodynamics as a Tool To Investigate the Mechanisms of Drugâ^'Receptor Interactions:Â Thermodynamics of Cytoplasmic Steroid/Nuclear Receptors in Comparison with Membrane Receptors. Journal of Medicinal Chemistry, 2005, 48, 2026-2035.	2.9	17

#	Article	IF	Citations
55	Development and characterization of PLGA nanoparticles as delivery systems of a prodrug of zidovudine obtained by its conjugation with ursodeoxycholic acid. Drug Delivery, 2014, 21, 221-232.	2.5	17
56	Nasal biocompatible powder of Geraniol oil complexed with cyclodextrins for neurodegenerative diseases: physicochemical characterization and in vivo evidences of nose to brain delivery. Journal of Controlled Release, 2021, 335, 191-202.	4.8	17
57	A Concerted Study Using Binding Measurements, X-ray Structural Data, and Molecular Modeling on the Stereochemical Features Responsible for the Affinity of 6-Arylpyrrolo[2,1-d][1,5]benzothiazepines toward Mitochondrial Benzodiazepine Receptors. Journal of Medicinal Chemistry, 1995, 38, 4730-4738.	2.9	16
58	Fabrication via a nonaqueous nanoprecipitation method, characterization and in vitro biological behavior of N6-cyclopentyladenosine-loaded nanoparticles. Journal of Pharmaceutical Sciences, 2009, 98, 4272-4284.	1.6	16
59	Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLCâ€“ESI-MS/MS analysis: Application to in vivo preclinical pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 901, 72-78.	1.2	16
60	Poly(lactic acid) microspheres for the sustained release of a selective A1 receptor agonist. Journal of Controlled Release, 2001, 73, 303-313.	4.8	14
61	Solid Lipid Microparticles for the Stability Enhancement of a Dopamine Prodrug. Journal of Pharmaceutical Sciences, 2010, 99, 4730-4737.	1.6	14
62	Design and formulation of Eudragit-coated zein/pectin nanoparticles for the colon delivery of resveratrol. European Food Research and Technology, 2020, 246, 2427-2441.	1.6	14
63	Uptake in the Central Nervous System of Geraniol Oil Encapsulated in Chitosan Oleate Following Nasal and Oral Administration. Pharmaceutics, 2019, 11, 106.	2.0	13
64	Versatile Nasal Application of Cyclodextrins: Excipients and/or Actives?. Pharmaceutics, 2021, 13, 1180.	2.0	13
65	Targeting Systems to the Brain Obtained by Merging Prodrugs, Nanoparticles, and Nasal Administration. Pharmaceutics, 2021, 13, 1144.	2.0	13
66	Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates. European Journal of Pharmaceutical Sciences, 2010, 41, 328-336.	1.9	12
67	Effect of a Fiber D-Limonene-Enriched Food Supplement on Intestinal Microbiota and Metabolic Parameters of Mice on a High-Fat Diet. Pharmaceutics, 2021, 13, 1753.	2.0	12
68	Odorants could elicit repair processes in melanized neuronal and skin cells. Neural Regeneration Research, 2017, 12, 1401.	1.6	11
69	Cocrystals of Nitrofurantoin: How Coformers Can Modify Its Solubility and Permeability Across Intestinal Cell Monolayers. Crystal Growth and Design, 2022, 22, 3090-3106.	1.4	10
70	Biochemical and pharmacological characterization of periodate-oxidized adenosine analogues at adenosine A1 receptors. Biochimica Et Biophysica Acta - Molecular Cell Research, 1995, 1267, 145-151.	1.9	9
71	Chitosan/heparin polyelectrolyte complexes as ion-paring approach to encapsulate heparin in orally administrable SLN: In vitro evaluation. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2021, 608, 125606.	2.3	9
72	Synthesis and inÂvitro stability of nucleoside 5â€²-phosphonate derivatives. European Journal of Medicinal Chemistry, 2012, 54, 202-209.	2.6	8

#	Article	IF	Citations
73	A novel hybrid drug between two potent anti-tubulin agents as a potential prolonged anticancer approach. European Journal of Pharmaceutical Sciences, 2016, 91, 50-63.	1.9	8
74	Polymeric nanomicelles based on inulin D Î±-tocopherol succinate for the treatment of diabetic retinopathy. Journal of Drug Delivery Science and Technology, 2021, 61, 102286.	1.4	8
75	Met-Ile-Phe-Leu derivatives: full and partial agonists of human neutrophil formylpeptide receptors. European Journal of Pharmacology, 2001, 411, 327-333.	1.7	7
76	Potential therapeutic effects of odorants through their ectopic receptors in pigmented cells. Drug Discovery Today, 2017, 22, 1123-1130.	3.2	7
77	Thermodynamic in vitro studies as a method to investigate the pharmacodynamic behavior of adenosine A1 receptor ligands. Pharmaceutical Research, 1999, 16, 1054-1058.	1.7	6
78	Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis. European Journal of Pharmacology, 2002, 448, 123-131.	1.7	6
79	An RPE cell line as a useful in vitro model for studying retinoic acid receptor Î²: expression and affinity. Bioscience Reports, 2008, 28, 327-334.	1.1	6
80	Estrogen metabolites in the release of inflammatory mediators from human amnion-derived cells. Life Sciences, 2011, 88, 551-558.	2.0	6
81	Dopamine-sensitive adenylyl cyclases in neuronal development: physiopathological and pharmacological implications. Drug Discovery Today, 2011, 16, 520-529.	3.2	5
82	Physicochemical stability of cabazitaxel and docetaxel solutions. European Journal of Hospital Pharmacy, 2015, 22, 150-155.	0.5	5
83	Peptide Derivatives as Agonists or Antagonists of Formylpeptide Receptors: Analysis of their Effects on Neutrophils. Mini-Reviews in Medicinal Chemistry, 2003, 3, 167-173.	1.1	3
84	Synthesis and biological evaluation of pro-drugs of GW196771, a potent glycine antagonist acting at the NMDA receptor. Il Farmaco, 2005, 60, 393-397.	0.9	3
85	Evidence for the presence of N-formyl-methionyl-leucyl-phenylalanine (fMLP) receptor ligands in human amniotic fluid and fMLP receptor modulation by physiological labour. Journal of Reproductive Immunology, 2005, 68, 71-83.	0.8	3
86	Conformational Aspects of Human Formyl-peptide Receptor Agonists. Arzneimittelforschung, 2003, 53, 793-798.	0.5	2
87	Drug Release from Pharmaceutical Co-Crystals: Are Therapeutic and Safety Properties of Active Pharmaceutical Substances Retained?. Current Drug Delivery, 2019, 16, 486-489.	0.8	1
88	Crystal and molecular structures of two adenosine receptor ligands: 1,3-dimethylxanthine-7-riboside monohydrate (DMX-7R), a partial A1 agonist, and 9-chloro-2-(furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine methane sulfonate (CGS 15943), a selective A2a antagonist. Journal of Chemical Crystallography, 1997, 27, 59-65.	0.5	1
89	Conformational Aspects of Human Formylpeptide Receptor Antagonists. Arzneimittelforschung, 1999, 49, 873-877.	0.5	0